Search results
Results from the Tech24 Deals Content Network
Bristol Myers Squibb stock tanked in April after management lowered the midpoint of its earnings outlook for 2024 from $7.25 per share to just $0.55 to account for a $12.1 billion IPRD charge ...
For premium support please call: 800-290-4726 more ways to reach us
Friday, Bristol Myers Squibb & Co (NYSE:BMY) posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for ...
Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by Forbes magazine. [ 46 ] In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot ...
Bristol Myers Squibb: A high-yield dividend stock with an attractive valuation. Bristol Myers Squibb, or BMS for short, is another well-established pharmaceutical company with a strong presence in ...
Let's see if Bristol-Myers Squibb Company (BMY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Source: Shutterstock. Bristol-Myers Squibb (NYSE:BMY) reported earnings per share of $1.18 for the second quarter of 2019.This is better than the company’s earnings per share of $1.01 from the ...
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $63.50, marking a -0.5% move from the previous day.